AgingResearch.NewsJoin free

Phase 2Recruiting

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)

Sponsor
Mirati Therapeutics Inc. (Industry)
Enrolment
170 planned
Conditions
Solid Tumors
Interventions
Adagrasib; Pembrolizumab; Cetuximab; Pemetrexed; Docetaxel; Irinotecan; Leucovorin; Oxaliplatin; Fluorouracil
Ages
adults, older adults
Registry
NCT07415031

Full record on ClinicalTrials.gov

From the registry

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.

Primary outcomes

  • Number of Participants With Adverse Events (AEs)
  • Number of Participants With AEs Leading to Treatment Discontinuation
  • Number of Participants With Serious Adverse Events (SAEs)
  • Number of Participants With AEs Leading to Death

History

  1. Primary completion expected

  2. Last registry update

  3. Started

  4. Registered